ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

40.80
-0.600001
(-1.45%)
Closed 11 December 8:00AM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
40.80
Bid
40.20
Offer
41.40
Volume
557
41.40 Day's Range 42.20
0.00 52 Week Range 0.00
Previous Close
41.40
Open
41.80
Last Trade
5
@
42
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
2.645 €
(224.94%)
354.38k
UQ1Uniqure NV
14.565 €
(110.66%)
49.65k
XE7CCardiff Oncology Inc
3.645 €
(57.79%)
147.73k
9DRGlimpse Group
1.20 €
(52.87%)
14.47k
KH6NewAmsterdam Pharma Company NV
25.00 €
(42.05%)
1.23k
TE9Teco 2030 ASA
0.0142 €
(-75.00%)
1.38M
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
KEHChinese People Holdings Co Ltd
0.0015 €
(-50.00%)
42.7k
PA8Paion AG
0.0132 €
(-45.90%)
844
1R6Alset AI Ventures Inc
0.048 €
(-31.91%)
101.8k
AXIAtos SE
0.0023 €
(-14.81%)
741.04M
D7GNel ASA
0.2702 €
(0.11%)
4.2M
PF8European Lithium Limited
0.026 €
(-2.99%)
2.1M
3CPXiaomi Corporation
3.8005 €
(-2.43%)
2.05M
TE9Teco 2030 ASA
0.0142 €
(-75.00%)
1.38M

Discussion

View Full Feed
jbsliverer jbsliverer 5 minutes ago
https://bsky.app/profile/billscher.bsky.social/post/3lcyfu3gpgc2r

https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:kd4cyu4rpkgjbym3gckhrivz/bafkreigoryjhxo7b4wrtc4oaefgklosq47qjihoummxka7yrg7rtwokl64@jpeg


.
Joe Burmeister Joe Burmeister 5 minutes ago
Try this

https://ioutcomes.com/investors/

Its interesting that the Lambs are willing to lease back 50 percent of their HQ thats up for sale. So maybe if they find a buyer then can pay back their debts to the vendors, and continue to run their business in their leased of
UBQU
jimr1717 jimr1717 7 minutes ago
ATMH is not QB listed now. It’s just in the SEC S1 filing.
Just another waving Red Flag from this scam.

They are just another pink sham.

No one is Fooled by such nonsense

https://www.otcmarkets.com/stock/ATMH/overview
ATMH
Carjockey2 Carjockey2 8 minutes ago
Hot off the $HMBL "X" press

https://x.com/sathyabrc/status/1866643977920987474?t=FcZHn77de9qf80zzvOFVWA&s=19

https://x.com/sathyabrc/status/1866634671552917662?t=MxEqdnCOKGRofdgVabeU6w&s=19

https://x.com/sathyabrc/status/1866642782443671775?t=BBCdiNBpC035
HMBL
mrfence mrfence 8 minutes ago
That makes so much sense because the Gooberment wants $0.05 per warrant. Sarcasm intended.
FNMA
JohnnyHydrogen JohnnyHydrogen 9 minutes ago
Kevin O'Leary proposes 'Wonder Valley' in Alberta, billed as world’s largest AI data centre park

Dang - the possibilities are off the chart.

https://calgaryherald.com/opinion/columnists/varcoe-kevin-oleary-proposes-ai-data-centre-park-alberta
FCEL
distrojunky distrojunky 9 minutes ago
HMMMMMM.
Soon, Can't be too soon
COOP
georgejjl georgejjl 10 minutes ago
Tesla is Morgan Stanley’s ‘Top Pick’ and gets a fresh new price target

https://www.teslarati.com/tesla-tsla-morgan-stanley-top-pick-fresh-new-price-target/

Good luck and GOD bless,
TSLA
JTORENCE JTORENCE 11 minutes ago
norisknorewardsnobrains Why don't you call it like it was a -huge dump..
NWBO
glenn1919 glenn1919 11 minutes ago
zone....................a/h
netmoney1999 netmoney1999 11 minutes ago
It should be a red flag to anyone who pays attention that all of Shaun's other 'companies' and tickers have also features a paid promoter while the price of those went into the toilet.

Wonder how long for this one to tank. Seems like only a matter of time... usually after a couple ba
ZENA
Golf4Food Golf4Food 12 minutes ago
Hero!
hedge_fun hedge_fun 12 minutes ago
Clake has never issued a PR. Never publicly…..

disclosed what's been recovered. Doesn't talk about who his operating partners are or who he funds or why.

It's call PRIVATE equity for a reason.

If the project fails the investors lose their money. That’s
SFRX
DewDiligence DewDiligence 13 minutes ago
GM throws in the towel on robotaxis:

https://www.wsj.com/business/autos/general-motors-scraps-cruise-robotaxi-program-ea3298a8 General Motors has scrapped its Cruise robotaxi program after nearly a decade and $10 billion in development [!], citing the time and costs needed to scale t
cjstocksup cjstocksup 14 minutes ago
https://x.com/RealJamesWoods/status/1865459366364606860
delerious1 delerious1 14 minutes ago
Enter Shikari - (pls) set me on fire - (Official Video)

https://www.youtube.com/watch?v=mvDFdLZJ-q0
IB_ IB_ 15 minutes ago
We still have a quota and can only purchase a limited amount of API ................

🙄🌈👸

IB_🤴
API
Joe Burmeister Joe Burmeister 15 minutes ago
They have to keep this POS scam company afloat so the Benz crime family (Paul & wife Kathy and their slimeball son Alex) can recoup on the billions of shares Ballas has “loaned” them for these cash bailouts over the years.

And Benz family wont allow a R/S as those converted billions
UBQU
cjstocksup cjstocksup 15 minutes ago
https://x.com/RealJamesWoods/status/1865459901037793690
meidiot meidiot 16 minutes ago
May I suggest you do real DD on this Company.
You may end up with "egg on your face".
GMPR
gitreal gitreal 16 minutes ago
How many naked air shares are floating around now...25 billion?

You need to borrow Alidare's tin foil hat. If he'll let you.
AABB
Eli's Gone Eli's Gone 16 minutes ago
Crochet and Sasaki would obviously be great pieces for any rotation---BP aside, we now need 1B, an OF, and an IF

Your Recent History

Delayed Upgrade Clock